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HCS, an aﬀ ordable instrument to assess haemoglobin 
Anaemia is a leading cause of maternal deaths 
and adverse pregnancy outcomes in low-income 
and middle-income countries. Overall, 12% of low 
birthweight, 19% of preterm births, and 18% of 
perinatal mortality are attributable to maternal 
anaemia.1 The prevention and timely management of 
anaemia is therefore essential to attain Sustainable 
Development Goal (SDG) 3 on ensuring healthy lives 
and promoting wellbeing. 
Accurate measurement of haemoglobin allows 
the identiﬁ cation and treatment of individuals with 
anaemia, controlling the severe consequences of this 
condition. Unfortunately, in the peripheral health 
services of low-income countries, where the capacity 
to identify individuals with anaemia is most needed, 
haemoglobin is usually assessed only by clinical 
examination (ie, assessment of conjunctival and palmar 
pallor), an approach requiring a long training time and 
vast clinical experience to be fairly accurate.2 
Ideally, to be deployed in low-income and middle-
income countries, a method to assess haemoglobin 
concentration should be reliable, low cost, and easy 
to use. To respond to this need, the Haemoglobin 
Colour Scale (HCS)3 was developed and its performance 
evaluated in several settings with encouraging results.3–6 
Its use was promoted by the WHO as a low-cost, good 
performance, and simple-to-use method, yet its use in 
low-income and middle-income countries has not been 
at the expected levels: since its marketing in 2001, only 
about 90 000 scales have been sold (Willun A, Copack 
FH & Co, personal communication). 
The systematic review by Heiko Marn and 
Julia Critchley in The Lancet Global Health7 provides 
an exhaustive summary of the current literature on 
the accuracy of the HCS in comparison with clinical 
diagnosis; the review concludes that the wide 
introduction of the HCS could reduce the number of 
patients missing the right diagnosis of anaemia by 20%. 
Additionally, this review contains an interesting 
novelty. Taking advantage of the fact that most of the 
included HCS evaluations compared the results of this 
method with the ones obtained by clinical evaluation 
(palmar or conjunctival pallor), Marn and Critchley 
were able to assess the potential performances of the 
combined use of the two methods and conclude that 
this approach could further greatly reduce the number 
of patients with a missed diagnosis of anaemia.
Marn and Critchley also identiﬁ ed one of the 
limitations of the HCS, noting that the training protocols 
have not been updated in several years. It is likely that, 
in addition to revising the thresholds of anaemia and its 
determinants, addressing this point will enable better 
results and a more standardised use of the instrument.
The results of this review conclude that, 15 years after 
its development, the HCS is an accurate, simple-to-use, 
and aﬀ ordable point-of-care device to quantitatively 
assess haemoglobin. We hope that the conﬁ rmation 
provided by Marn and Critcheery that, 15 years after his 
development, the HCS remains the most simple to use 
and aﬀ ordable device to assess the haemoglobin, could 
further promote its use. 
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